CoV Biotechnology is an early-stage Singapore-based biotechnology company focusing on inducing broad, pan-sarbecovirus immune responses to address the evolving and mutating nature of the coronavirus.
CoV Biotechnology is tracked in the Tech.eu funding database. Based in Singapore, Singapore; active in Healthtech. Acquired by Leyden Labs in 2025. Data as of 24 Aug 2026.
